Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Kiesnowski

Plastic Surgery Appleton, WI Medical Doctor

NPI 1285607317 CMS profile 1140871

5605 Waterford Ln, Appleton, WI 54913

Open in the dashboard

General payments

$195,643

339 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Kiesnowski of Appleton, WI is reported in the CMS Open Payments database as having received $195,643 across 339 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,908 12
2024 General $9,740 18
2023 General $24,759 60
2022 General $25,215 42
2021 General $24,590 41
2020 General $13,655 24
2019 General $89,776 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Kiesnowski
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Brian Kiesnowski were reported at $7,908. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Brian Kiesnowski Plastic Surgery median Middle half National median
2019 $89,776 $371 $122–$1,483 $163
2020 $13,655 $158 $52–$438 $114
2021 $24,590 $249 $87–$752 $132
2022 $25,215 $274 $102–$793 $149
2023 $24,759 $299 $113–$891 $160
2024 $9,740 $361 $124–$1,062 $164
2025 $7,908 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $160,811 275 payments
  2. Osiris Therapeutics Inc. $32,036 48 payments
  3. Integra LifeSciences Corporation $2,341 2 payments
  4. GlaxoSmithKline, LLC. $120 1 payment
  5. KCI USA, Inc $112 1 payment
  6. Mentor Worldwide LLC $46 3 payments
  7. Pacira Pharmaceuticals Incorporated $39 2 payments
  8. AbbVie, Inc. $31 1 payment
  9. Allergan Inc. $30 1 payment
  10. Organogenesis Inc. $24 1 payment
  11. Other $54 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $148,688 50 payments
  2. Travel and Lodging $32,048 169 payments
  3. Consulting Fee $7,340 3 payments
  4. Food and Beverage $5,238 116 payments
  5. Long term medical supply or device loan $2,329 1 payment
Products named General payments · program years 2019–2025
  1. Stravix Other Advanced Wound Management $100,291 154 payments
  2. STRAVIX Extremities & Limb Restoration $77,448 137 payments
  3. GRAFIX PL $73,562 124 payments
  4. GRAFIX Other Advanced Wound Management $64,021 88 payments
  5. GrafixPL $59,752 78 payments
  6. GRAFIX Other Advanced Wound Management $53,149 78 payments
  7. STRAVIX PL $41,152 80 payments
  8. Grafix PL PRIME $41,040 77 payments
  9. GRAFIX XC Other Advanced Wound Management $39,948 66 payments
  10. GRAFIX XC Other Advanced Wound Management $36,079 59 payments
  11. Other $100,399 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$28,694

Medicare's payments for the services billed

Medicare patients

94

Average age 73

Services billed

297

64 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 53%
Ischemic heart disease 31%
Depression 31%
Chronic kidney disease 27%
Diabetes 24%
Atrial fibrillation 21%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record